Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells

Rong Guo1 | Yong Li2 | Zhijie Wang1 | Hua Bai1 | Jianchun Duan1 | Shuhang Wang1 | Lvhua Wang3 | Jie Wang1

1Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Laboratory Animal, Peking University Cancer Hospital and Institute, Beijing, China
3Department of Radiation Therapy, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Correspondence
Jie Wang, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Email: zhuhx163@163.com

Funding information
Beijing Municipal Natural Science Foundation, Grant/Award Number 7152029, 7172045; National Key Research and Development Project Precision Medicine Special Research, Grant/Award Number 2016YFC0902300; National Natural Science Foundation of China, Grant/Award Number 81101778, 81472206; CAMS Innovation Fund for Medical Sciences, Grant/Award Number CIFMS 2016-12M-3-008; National Natural Science Foundation Key Program, Grant/Award Number 81330062, 81630071; National High Technology Research and Development Program 863, Grant/Award Number SSZ2015AAA020403

Some driver gene mutations, including epidermal growth factor receptor (EGFR), have been reported to be involved in expression regulation of the immunosuppressive checkpoint protein programmed cell death ligand 1 (PD-L1), but the underlying mechanism remains obscure. We investigated the potential role and precise mechanism of EGFR mutants in PD-L1 expression regulation in non-small-cell lung cancer (NSCLC) cells. Examination of pivotal EGFR signaling effectors in 8 NSCLC cell lines indicated apparent associations between PD-L1 overexpression and phosphorylation of AKT and ERK, especially with increased protein levels of phospho-IκBα (p-IκBα) and hypoxia-inducible factor-1α (HIF-1α). Flow cytometry results showed stronger membrane co-expression of EGFR and PD-L1 in NSCLC cells with EGFR mutants compared with cells carrying WT EGFR. Additionally, ectopic expression or depletion of EGFR mutants and treatment with EGFR pathway inhibitors targeting MEK/ERK, PI3K/AKT, mTOR/S6, IκBα, and HIF-1α indicated strong accordance among protein levels of PD-L1, p-IκBα, and HIF-1α in NSCLC cells. Further treatment with pathway inhibitors significantly inhibited xenograft tumor growth and p-IκBα, HIF-1α, and PD-L1 expression of NSCLC cells carrying EGFR mutant in nude mice. Moreover, immunohistochemical analysis revealed obviously increased protein levels of p-IκBα, HIF-1α, and PD-L1 in NSCLC tissues with EGFR mutants compared with tissues carrying WT EGFR. Non-small-cell lung cancer tissues with either p-IκBα or HIF-1α positive staining were more likely to possess elevated PD-L1 expression compared with tissues scored negative for both p-IκBα and HIF-1α. Our findings showed important roles of phosphorylation activation of AKT and ERK and potential interplay and cooperation between NF-xB and HIF-1α in PD-L1 expression regulation by EGFR mutants in NSCLC.

Abbreviations: ADC, adenocarcinoma; APC, allophycocyanin; EGFR, epidermal growth factor receptor; HIF-1α, hypoxia-inducible factor-1α; IKK, IκB kinase; NSCLC, non-small-cell lung cancer; NF-xB, nuclear factor-xB; p-, phosphorylated; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; PE, phycoerythrin; SCC, Squamous cell carcinoma; TKI, tyrosine kinase inhibitor.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
1 | INTRODUCTION

Lung cancer is the leading cause of cancer-related death around the world. There are approximately 1.30 million new cases and 1.20 million deaths due to lung cancer every year. Non-small-cell lung cancer accounts for approximately 80% of lung cancer cases. Since the beginning of the 21st century, molecular targeting therapies such as EGFR-TKIs have shown promising curative effects in NSCLC patients. However, the overall 5-year survival rate of NSCLC has not apparently been improved due to primary or secondary drug resistance. Therefore, new treatments for lung cancer are urgently needed.

Recently, immunotherapies targeting the PD-1 coinhibitory receptor and its adaptor-programmed death ligand 1 (PD-L1) by mAbs have represented a major breakthrough in the treatment of various advanced tumors, including NSCLC. Programmed cell death-1 belongs to the CD28 family and is a type I transmembrane protein mainly expressed on activated T cells. Its ligand PD-L1 belongs to the B7 family and is widely expressed on dendritic cells, macrophages, activated T and B cells, and non-immune cells including cancer cells. As important immune checkpoint molecules, PD-1/PD-L1 interaction suppresses the growth and function of effector T cells by inducing T cell apoptosis, anergy, and exhaustion and regulating the secretion of various cytokines. Tumor cells with PD-L1 overexpression have been reported to be related to aggressive behavior and worse disease control and treatment outcomes.

A growing amount of evidence has elucidated the intrinsic and extrinsic mechanisms of PD-L1 expression regulation in cancer cells. Inflammatory cytokines, such as IFN-γ, can induce PD-L1 expression through the MEK/ERK or JAK/STAT pathway. The EML4-ALK fusion gene and loss of Lkb1 and PTEN have been reported to be involved in intrinsic regulation of PD-L1 expression in NSCLC. Mutated EGFR is the most important driver gene in NSCLC and up to 47.9% of Asian patients harbor EGFR, sensitizing mutations to EGFR-TKIs. In 2013, Akbay et al. first showed that EGFR mutant in bronchial epithelial cells induced PD-L1 expression to facilitate immune escape in EGFR-driven lung tumors. In 2015, D’Incecco et al. reported that positive PD-L1 expression was significantly associated with EGFR mutations in a cohort of 125 NSCLC patients. However, the potential role and precise molecular mechanism of PD-L1 expression regulation by EGFR mutants remain to be explored.

In the present study, we investigated the EGFR status, activation of pivotal EGFR signaling cascades, and PD-L1 expression in a panel of NSCLC cells and observed apparent associations between PD-L1 overexpression and phosphorylation activation of ERK and AKT, especially with increased protein levels of p-IκBα and HIF-1α. Additionally, we undertook flow cytometry analysis to examine the cell surface expression of EGFR and PD-L1 in NSCLC cells with different EGFR status. More over, ectopic expression or depletion of WT EGFR and EGFR mutants or specific pathway inhibitors was used to elucidate the regulation mechanism of PD-L1 expression by EGFR in NSCLC cells or xenograft mouse models. The correlations between EGFR status, p-IκBα, HIF-1α, and PD-L1 protein levels were further analyzed in 149 human NSCLC tissue samples.
transfections were used as controls. At 48 hours post-transfection, and data were analyzed with BD Accuri C6 software.

0.2% Tween 20/PBS buffer 4 times, membranes were incubated used DMSO-treated cells as control. After treatment for 48 hours, with cold staining buffer to a final concentration of 1 × 10^6 cells/mL. The cells were washed twice with staining buffer, PE Mouse IgG1 and APC Mouse IgG2b, were used according to the manufacturer's instructions. The cells were washed twice with staining buffer to remove unbound Abs and then analyzed on a flow cytometer (Accuri C6; BD Biosciences). Side-scatter and forward-scatter profiles were used to eliminate cell doublets. Cells were routinely sorted twice and data were analyzed with BD Accuri C6 software.

2.4 | Flow cytometry

The NSCLC cells were collected and washed twice in cold flow cytometry staining buffer (PBS containing 0.2% [w/v] BSA), then resuspended with cold staining buffer to a final concentration of 1 × 10^6 cells/mL. Cell suspension was aliquoted into 100 µL to each tube, and the primary Abs, PE-PD-L1 and APC-EGFR, were added and incubated for 30 minutes on ice in the dark. The respective isotype control Abs, PE Mouse IgG1 and APC Mouse IgG2b, were used according to the manufacturer's instructions. The cells were washed twice with staining buffer to remove unbound Abs and then analyzed on a flow cytometer (Accuri C6; BD Biosciences). Side-scatter and forward-scatter profiles were used to eliminate cell doublets. Cells were routinely sorted twice and data were analyzed with BD Accuri C6 software.

2.5 | Pathway inhibition experiment

H1975 cells carrying EGFR (L858R + T790M) were selected for EGFR pathway inhibition experiments. H1975 cells received 2 dose treatments (1× and 3×) of each pathway inhibitor (3 and 9 µmol/L U0126, 15 and 45 µmol/L LY294002, 4 and 12 nmol/L rapamycin, 2.5 and 7.5 µmol/L BAY11-7082, and 25 and 75 µmol/L PX-478). We used DMSO-treated cells as control. After treatment for 48 hours, total cellular proteins were extracted for further analysis.

2.6 | Western blot analysis

The treated cells were lysed on ice for 25 minutes using RIPA Lysing Buffer supplemented with protease inhibitors, and the solution was cleared by centrifugation at 14 000 g for 20 minutes. The total protein concentration was quantified utilizing a BCA protein assay kit, and equal amounts of proteins (20-40 µg/lane) were separated on 10%-12% SDS-PAGE gels and electrotransferred to PVDF membranes. The membranes were then blocked with 5% nonfat milk and probed with specific primary Abs: anti-EGFR, anti-p-ERK1/2 (pT202/ pT204), anti-ERK1/2, anti-HIF-1α, anti-PD-L1, anti-p-AKT (Ser473), anti-AKT, anti-p-LxBα (Ser32/36), anti-S6, anti-p-S6 (Ser235/236), anti-His, and anti-Actin (1:1000-1:5000 dilution). After washing with 0.2% Tween 20/PBS buffer 4 times, membranes were incubated with HRP-conjugated secondary Ab and visualized using the ECL system (GE Healthcare, Little Chalfont, UK).

2.7 | In vivo animal model experiment

Female BALB/c nude mice (5-6 weeks old) were obtained from Beijing Vital River Laboratory Animal Company (Beijing, China) and maintained under specific pathogen-free conditions in the Laboratory Animal Department of Beijing Cancer Hospital and Institute (Beijing, China). Care of experimental animals was in accordance with institutional animal care and use committee guidelines.

Non-small-cell lung cancer cells H1975 were injected s.c. into the lateral root of posterior limb of nude mouse (3 × 10^5 cells/mouse). The day of cell injection was designated as day 0. The tumor size of H1975 xenograft mouse models was monitored every 4 days using digital calipers, and tumor volumes were calculated according to the following formula: tumor volume (mm^3) = (short axis in mm)^2 × (long axis in mm) × 0.52. When the tumor size reached 100-150 mm^3, mice were randomly divided into 5 experimental groups (5 mice per group) and treated with U0126 (i.p., at 20 mg/kg), LY294002 (i.p., at 15 mg/kg), BAY11-7082 (i.p., at 5 mg/kg), PX-478 (p.o. gavage at 20 mg/kg), or an equivalent volume of DMSO (used as control). All 5 inhibitors were given once every 3 days within 16 days. Mice were killed and tumors were photographed on indicated days. Total proteins of tumors of each group were extracted, and western blot analysis was used to test the expression of p-LxBα, HIF-1α, and PD-L1. The remaining part of each tumor was routinely formalin-fixed, paraffin-embedded, serially sectioned, and subjected to immunohistochemistry to examine the expression of PD-L1 protein, described below.

2.8 | Immunohistochemical analysis

For immunohistochemistry analysis of the expression of p-LxBα, HIF-1α, and PD-L1, tumor samples were obtained from 149 NSCLC patients who had undergone surgical resection at Beijing Cancer Hospital. Tumor tissues obtained from xenotransplanted tumor models were also included. All the specimens had been routinely formalin-fixed, paraffin-embedded, and serially sectioned at 5 µm in thickness.

All tissues were stained using the streptavidin-peroxidase immunohistochemical method. Briefly, the slides were deparaffinized in xylene, rehydrated in graded ethanol, and then treated with PBS containing 3% hydrogen dioxide to block endogenous peroxidase. Slides were preincubated in 10% goat serum to block nonspecific binding and then incubated with specific primary Abs against PD-L1 (ab205921; Abcam), HIF-1α (ab51608; Abcam), and p-LxBα (#9246; Cell Signaling Technology) separately at 4°C overnight. Sections were subsequently rinsed and incubated with biotin-conjugated IgG from Santa Cruz Biotechnology (Santa Cruz, CA, USA) with 1:10 000 dilution for 15 minutes and then with streptavidin-peroxidase conjugate for 15 minutes. The signals were developed with DAB-H2O2 solution. The slides were counterstained with 5% hematoxylin and then examined by light microscopy. Sections without primary Ab treatment were used as negative control. Immunohistochemical evaluation of PD-L1, p-LxBα, and HIF-1α in NSCLC specimens was based on the intensity and extent of tumor cell staining. Moderate to strong cell surface PD-L1 expression in ≥5%, p-LxBα cytoplasm staining in ≥10%, and HIF-1α nuclear staining in ≥10% of tumor cells were defined as positive results. All NSCLC sections were histopathologically reviewed by 2 trained pathologists.

6-well plates (2 × 10^5 cells/well). The next day, 2 µg of each expression vector or siRNA sequence was mixed with 6 µL Lipofectamine 2000 (Invitrogen) plus 250 µL Opti-MEM medium (Invitrogen) for 20 minutes and then added to cells. The empty vector and mismatched siRNA transfections were used as controls. At 48 hours post-transfection, cells were harvested for further analysis.
2.9 | DNA extraction and EGFR genotyping

The cancer tissues from all the 149 NSCLC samples were separated using manual microdissection and incubated overnight at 56°C in 50 μL digestion buffer containing 10 mg/mL proteinase K, 0.5% Tween-20, 1 mmol/L EDTA, pH 8.0, and 50 mmol/L Tris, pH 8.5. The next day, proteinase K was inactivated by incubation of the samples at 100°C for 10 minutes. DNA samples were stored at −80°C until analysis. The EGFR status was also determined by PCR direct sequencing using the primers as previously reported.26

Polymerase chain reaction was carried out using 50 ng each sample DNA as template and negative controls (extracted slices of paraffin blocks containing no tissue) were included. The EGFR status was identified by direct sequencing using the ABI 3700 DNA sequencer (PE Applied Biosystems).

2.10 | Statistical analysis

SPSS 16.0 software (SPSS, Chicago, IL, USA) was used in determining statistical significance. The continuous variables from different groups are shown as mean ± SD and were compared using t tests. The correlations among EGFR status, p-ιxBα, HIF-1α, and PD-L1 protein levels in NSCLC specimens were analyzed using χ² tests. Corresponding P values < .05 were considered statistically significant.

3 | RESULTS

3.1 | Activation of EGFR signaling pathway and PD-L1 expression in NSCLC cells

To investigate the correlation between the activation of the EGFR pathway and PD-L1 expression in NSCLC cells, we examined the EGFR status and expression levels of EGFR, its pivotal downstream effectors (p-ERK1/2, ERK1/2, p-AKT, AKT, p-ιxBα, and HIF-1α), and PD-L1 in a total of 8 NSCLC cells. Sequencing results showed that 4 NSCLC cells possessed EGFR mutation (HCC827, HCC2935, H1650 with EGFR [e19del] and H1975 with EGFR [L858R + T790M], respectively). As shown in Figure 1A, western blot results revealed obviously elevated phosphorylation levels of ERK1/2, AKT, and ιxBα and increased expression levels of HIF-1α and PD-L1 in 3 NSCLC cells with EGFR mutants and the highest or a moderate expression of EGFR (HCC827, HCC2935, and H1975), in comparison with the other NSCLC cells carrying WT EGFR (H522, H661, H1792, and H1299) or cells with EGFR mutant but relatively low EGFR expression (H1650). Notably, apparent associations of PD-L1 overexpression with increased p-ιxBα and HIF-1α protein levels were observed in these 3 NSCLC cell lines with EGFR mutants. Due to the important roles of cell surface expression of EGFR and PD-L1, further flow cytometry analysis was carried out using specific Abs labeled with different fluorescent proteins.

The percentages of cells with both EGFR and PD-L1 expression on cell surface were 88.9%, 55.8%, and 62.7% in 3 NSCLC cell lines with mutated EGFR (HCC827, HCC2935, and H1975, respectively), which were obviously higher than the remaining NSCLC cell lines carrying WT EGFR (Figure 1B).

3.2 | Effects of activation or inhibition of EGFR signaling pathway on PD-L1 expression regulation in NSCLC cells

To compare the effects of WT EGFR and different EGFR mutants on PD-L1 expression. H661 cells were transfected with WT EGFR or EGFR mutant expression vectors (e19del, e19del + T790M, L858R, and L858R + T790M). As shown in Figure 2A, ectopic expression of WT EGFR significantly elevated phosphorylation levels of ERK, AKT, S6, and ιxBα and expression levels of HIF-1α and PD-L1 in H661 cells. In comparison with WT EGFR, transfection of all 4 EGFR mutants showed stronger capability of activating downstream signaling pathway effectors and upregulating PD-L1 protein expression. Notably, transfection of EGFR (e19del + T790M) or EGFR (L858R + T790M) mutant showed stronger upregulation effects than EGFR (e19del) or EGFR (L858R), respectively. Subsequent specific siRNA-induced depletion of EGFR mutant and WT EGFR obviously suppressed signaling pathway activation and PD-L1 expression. Notably, transfection of EGFR (e19del + T790M) or EGFR (L858R + T790M) mutant showed stronger upregulation effects than EGFR (e19del) or EGFR (L858R), respectively. Subsequent specific siRNA-induced depletion of EGFR mutant and WT EGFR obviously suppressed signaling pathway activation and PD-L1 expression in H1975 and H1299 cells, respectively (Figure 2B,C). To elucidate the precise roles of signaling effectors of the EGFR pathway in PD-L1 expression regulation, 5 kinds of pathway inhibitor (U0126, LY294002, Rapamycin, BAY11-7082, and PX-478) were used to treat H1975 cells separately. As shown in Figure 2D, treatment with the 5 inhibitors induced obviously decreased protein levels of p-ιxBα, HIF-1α, and PD-L1 and displayed significant dose-dependent relationship in H1975 cells, with BAY11-7082 and PX-478 treatments playing the strongest roles.

3.3 | Treatment with EGFR pathway inhibitors suppressed tumor growth and PD-L1 expression in xenograft mouse model

To further testify the roles of signaling effectors (p-ERK, p-AKT, p-ιxBα, and HIF-1α) in PD-L1 expression regulation by EGFR mutant in NSCLC in vivo, a xenotransplanted tumor mouse model bearing H1975 cells was established and received treatments of corresponding pathway inhibitors. As shown in Figure 3A, the tumor burdens were significantly decreased by treatments with U0126, LY294002, BAY11-7082, and PX-478 compared with control group (DMSO). The greatest inhibition effects on tumor growth were observed in PX-478 and BAY11-7082 groups.

Western blot analysis showed that the protein levels of HIF-1α, p-ιxBα, and PD-L1 were significantly downregulated to varying degrees in transplanted tumor tissues of all 4 pathway inhibitor groups compared with the control group. Further immunohistochemistry analysis confirmed the change in PD-L1 protein level in each experimental group. Notably, PX-478 and BAY11-7082 groups showed the strongest inhibition effects on PD-L1 expression (Figure 3B,C).
3.4 | Correlations among EGFR status, p-\(\kappa\)B\(\alpha\), HIF-1\(\alpha\), and PD-L1 protein levels in NSCLC tissues

The representative examples of p-\(\kappa\)B\(\alpha\), HIF-1\(\alpha\), and PD-L1 staining are shown in Figure 4. The expression patterns of PD-L1 according to clinical characteristics, EGFR status, p-\(\kappa\)B\(\alpha\) protein level, and HIF-1\(\alpha\) expression are summarized in Table 1. A total of 54 (36.2%), 64 (43.0%), and 53 (35.6%) of 149 NSCLC specimens were scored p-\(\kappa\)B\(\alpha\), HIF-1\(\alpha\), and PD-L1 staining positive, respectively. The expression of PD-L1 protein was not significantly associated with clinical characteristics. The proportion of tissues with positive PD-L1 staining was much higher in NSCLC tissues with either p-\(\kappa\)B\(\alpha\) or HIF-1\(\alpha\) positive staining than in tissues with...
FIGURE 2  Effects of activation or inhibition of the epidermal growth factor receptor (EGFR) signaling pathway on programmed cell death ligand 1 (PD-L1) expression in non-small-cell lung cancer cells. A, H661 cells transfected with WT EGFR (wt-EGFR) or EGFR mutant expression vectors (e19del, e19del + T790M, L858R, and L858R + T790M) showed apparently elevated protein levels of phosphorylated (p-) ERK, p-AKT, p-S6, p-IκBα, hypoxia-inducible factor-1α (HIF-1α), and PD-L1. *P < .01 vs wt-EGFR transfection. B,C Specific siRNA (si-EGFR) transfection induced significantly downregulated EGFR expression, followed by obviously decreased protein levels of p-ERK, p-AKT, p-S6, p-IκBα, HIF-1α, and PD-L1 in H1975 (B) and H1299 (C) cells, respectively. D, H1975 cells received 2 dose treatments (1× and 3×) of 5 kinds of pathway inhibitor, with DMSO-treated cells used as control. Actin was used as internal control and the graph indicates the relative protein levels of p-IκBα, HIF-1α, and PD-L1. Mean ± SD values for continuous variables of 3 experiments. *P < .01 and **P < .05 vs DMSO group.
both p-IkBα and HIF-1α negative staining (44.4% vs 22.0%; \( P = .005 \)). As for EGFR genotyping, PCR amplification was successful in 142 of 149 NSCLC samples and EGFR mutants were detected in 46 (32.4%) of 142 NSCLC specimens. The NSCLC tissues harboring EGFR mutants presented significantly increased positive rate of PD-L1 expression in comparison with tissues with WT EGFR (47.8% vs 30.2%, \( P = .041 \)).

Elevated protein levels of p-IkBα and HIF-1α were also detected in tissues carrying EGFR mutants compared to tissues with the WT EGFR gene (56.0% vs 44.0%, \( P = .029 \) and 56.4% vs 43.6%, \( P = .012 \), respectively; Table 2). Additionally, the proportion of tissues with positive p-IkBα staining was significantly higher in NSCLC tissues with HIF-1α positive staining than HIF-1α negative staining (59.2% vs 40.8%; \( P = .002 \)), as shown in Table 3.

4 | DISCUSSION

Overexpression of PD-L1 has been detected in various kinds of human tumors, including NSCLC, and has been reported to be a poor prognostic indicator of overall survival and a predictive marker of good response to new immunotherapy drugs.\(^{27,28}\) Some driver gene mutations including EGFR have been reported to be involved in intrinsic regulation of PD-L1 expression in various tumors, including NSCLC.\(^{29}\) Epidermal growth factor receptor is a member of the ErbB family of receptor tyrosine kinases. EGFR mutants promote tumorigenesis of NSCLC by constitutively activating downstream signaling effectors, including PI3K/AKT, RAS/ERK, and others.\(^{30,31}\) Activated AKT, as a key downstream effector of the EGFR pathway, has been reported to activate NF-κB and thereby regulate PD-L1 expression.\(^{32}\) As an important transcription factor, NF-κB transactivates PD-L1 expression by binding directly to the PD-L1 promoter.\(^{33,34}\) NF-κB is bound and inhibited by IκBα in the cytoplasm of unstimulated cells. Upon stimulation, IκBα are phosphorylated by upstream IKK kinases and NF-κB is released and translocates into nucleus to transcript target genes, including PD-L1. By phosphorylation of IKK kinases, which in turn phosphorylate IκBα, activation of PI3K/AKT can further activate NF-κB.\(^{35-37}\)
In the present study, we investigated the association of EGFR status and EGFR signaling pathway activation with PD-L1 expression in 8 human NSCLC cell lines. Genotyping and western blot results showed that the EGFR status and EGFR expression together affected phosphorylation activation of ERK1/2, AKT, and IκBα and expression of HIF-1α and PD-L1 in NSCLC cells. Notably, strong accordance between PD-L1 expression and protein levels of p-IκBα and HIF-1α was observed in the majority of NSCLC cells examined. Further flow cytometry analysis indicated that NSCLC cells with mutated EGFR showed clearly higher percentages of cells that were both EGFR and PD-L1 positive on the cell surface than the remaining NSCLC cell lines carrying WT EGFR. Another important transcription factor, HIF-1α, increases the expression of PD-L1 in hypoxic cancer cells by binding directly to the hypoxia response element in the PD-L1 promoter.38,39 Upregulated HIF-1α expression by a reduction in oxygen-dependent degradation in hypoxia leads to the expression of genes involved in tumor angiogenesis, metastasis/migration, glucose metabolism, cell proliferation, chemoresistance, and immune adaptation.40-42 Apart from hypoxia, genetic changes and abnormal activation of important signaling pathways in tumors can induce HIF-1α expression under normoxia conditions. VHL, PTEN, BRAF, and SDH gene mutations have been reported to regulate HIF-1α expression under normoxia.40,43 Activation of AKT upregulates HIF-1α protein translation through downstream component mTOR/S6.44

Our sequencing results revealed EGFR (L858R + T790M) mutant in H1975 cells and WT EGFR in H661 and H1299 cells, and these 3 cell lines were used to investigate the precise molecular mechanism of PD-L1 expression regulation by EGFR in NSCLC cells. H661 cells transfected with 4 kinds of common EGFR mutant or H1975 cells with si-EGFR showed obviously up- or downregulated protein levels of p-ERK, p-AKT, p-IκBα, HIF-1α, and PD-L1, respectively. In contrast, H661 cells transfected with WT EGFR or H1299 cells with si-EGFR showed relatively mild changes in the protein levels mentioned above. We further treated H1975 cells with 5 kinds of pathway inhibitor (U0126, LY294002, Rapamycin, BAY11-7082, and PX-478) to explore the potential roles of pivotal signaling effectors of the EGFR pathway in regulation of PD-L1 expression in NSCLC cells. Western blot analysis revealed significantly suppressed protein levels of p-IκBα, HIF-1α, and PD-L1 in H1975 cells treated with all 5 inhibitors, with BAY11-7082 and PX-478 showing the strongest inhibitory effects. These results suggested important roles of p-AKT and p-ERK and potential interplay and cooperation between NF-κB and HIF-1α in regulation of PD-L1 expression by EGFR mutants in NSCLC cells. It has been reported that activated NF-κB can directly bind to the promoter of HIF-1α and promote HIF-1α transcription under hypoxia or normoxia conditions in multiple cells, including cancer cells.45,46 Notably, some studies have revealed a positive feedback loop between HIF-1α and NF-κB pathways. Hypoxia-inducible factor-1α can induce transcription of IKKβ through the hypoxia response element present in the promoter of the IKKβ gene and mediate consequent nuclear translocation and activation of NF-κB.47 Hypoxia-inducible factor-1α has also been reported to directly transcript NF-κB expression under hypoxia.45,48 Based on previous research reports and our existing research findings, we developed a possible model for PD-L1 expression regulation by EGFR mutants (Figure 5).

We next determined the roles of pivotal EGFR signaling effectors in regulation of PD-L1 expression in NSCLC in vivo. A xenotransplanted tumor mouse model bearing H1975 cells was established and treated with corresponding pathway inhibitors. Subsequent western blot and immunohistochemistry analyses showed that the protein levels of p-IκBα, HIF-1α, and PD-L1 were significantly downregulated to varying degrees in all inhibitor groups, with PX-478 and BAY11-7082 treatments displaying the strongest inhibition effects on PD-L1.
expression. These results were consistent with our research findings in vitro and further suggested the important roles of HIF-1α and p-LxBα in PD-L1 expression regulation by EGFR mutants in NSCLC.

To investigate the correlations among EGFR mutants, pivotal EGFR signaling effectors, and PD-L1 expression, we further examined EGFR

---

**TABLE 1** Associations of clinical and genetic factors with programmed cell death ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer (n = 149)

| Variable          | Total | PD-L1, n (%) | P-valuea |
|-------------------|-------|--------------|----------|
| Age, years        |       | Positive     | Negative |
| ≤60               | 61    | 24 (39.3)    | 37 (60.7) | 0.423    |
| >60               | 88    | 29 (33.0)    | 59 (67.0) |          |
| Gender            |       |              |          |
| Male              | 96    | 35 (36.5)    | 61 (63.5) | 0.761    |
| Female            | 53    | 18 (34.0)    | 35 (66.0) |          |
| Smoking status    |       |              |          |
| Smoker            | 54    | 23 (42.5)    | 31 (57.5) | 0.177    |
| Nonsmoker         | 95    | 30 (31.6)    | 65 (68.4) |          |
| Pathology         |       |              |          |
| ADC               | 76    | 25 (32.9)    | 51 (67.1) |          |
| SCC               | 73    | 28 (38.4)    | 45 (61.6) | 0.486    |
| TNM stage         |       |              |          |
| I                 | 14    | 3 (21.4)     | 11 (78.6) | 0.529    |
| IIa               | 63    | 21 (33.3)    | 42 (66.7) |          |
| IIb               | 59    | 23 (39.0)    | 36 (61)   |          |
| III               | 13    | 6 (46.1)     | 7 (53.9)  |          |
| Lymph node metastasis |   |              |          |
| Positive          | 72    | 29 (40.3)    | 43 (59.7) | 0.246    |
| Negative          | 77    | 24 (31.2)    | 53 (68.8) |          |
| EGFR statusb      |       |              |          |
| Wild-type         | 96    | 29 (30.2)    | 67 (69.8) | 0.041    |
| Mutated           | 46    | 22 (47.8)    | 24 (52.2) |          |
| p-LxBα expression |       |              |          |
| Positive          | 54    | 23 (42.6)    | 31 (57.4) | 0.177    |
| Negative          | 95    | 30 (31.6)    | 65 (68.4) |          |
| HIF-1α expression |       |              |          |
| Positive          | 64    | 27 (42.2)    | 37 (57.8) | 0.143    |
| Negative          | 85    | 26 (30.6)    | 59 (69.4) |          |
| p-LxBα and HIF-1α expression | |              |          |
| Positivec         | 90    | 40 (44.4)    | 50 (55.6) | 0.005    |
| Negativec         | 59    | 13 (22.0)    | 46 (78.0) |          |

---

**TABLE 2** Association of epidermal growth factor receptor (EGFR) status with phosphorylated (p-)LxBα or hypoxia-inducible factor-1α (HIF-1α) expression in patients with non-small-cell lung cancer (n = 142)

| Variables | Total | WT | Mutated | P-valueb |
|-----------|-------|----|---------|----------|
| p-LxBα expression |       |    |         |          |
| Positive   | 50    | 28 (56.0) | 22 (44.0) |          |
| Negative   | 92    | 68 (73.9) | 24 (26.1) | 0.029    |
| HIF-1α expression |       |    |         |          |
| Positive   | 62    | 35 (56.4) | 27 (43.6) |          |
| Negative   | 80    | 61 (76.2) | 19 (23.8) | 0.012    |

---

**TABLE 3** Association of phosphorylated (p-)LxBα expression with hypoxia-inducible factor-1α (HIF-1α) expression in patients with non-small-cell lung cancer (n = 149)

| Variable | Total | Positive | Negative | P-valuea |
|----------|-------|----------|----------|----------|
| p-LxBα expression |       |         |          |          |
| Positive  | 54    | 32 (59.2) | 22 (40.8) | 0.002    |
| Negative  | 95    | 32 (33.6) | 63 (66.4) |          |

---

**FIGURE 5** Flowchart of programmed cell death ligand 1 (PD-L1) expression regulation by epidermal growth factor receptor (EGFR) mutants through downstream signaling effectors phosphorylated (p-)AKT, p-ERK, nuclear factor-κB (NF-κB), and hypoxia-inducible factor-1α (HIF-1α). IKK, IκB kinase

status and protein levels of p-LxBα, HIF-1α, and PD-L1 in 149 human NSCLC tissues. The mutation rate of the EGFR gene was 32.4% in this NSCLC patient group, and NSCLC tissues carrying EGFR mutants showed elevated protein levels of PD-L1, p-LxBα, and HIF-1α, compared to tissues with WT EGFR (P = .041, .029, and .012, respectively), which was supported by various previous reports that PD-L1 expression was upregulated in NSCLC tissues harboring EGFR mutations.21,49,50 We
next undertook an association analysis of HIF-1α and p-IkBα positive staining with PD-L1 expression and revealed that NSCLC tissues with either HIF-1α or p-IkBα positive staining presented significantly increased positive rates of PD-L1 expression compared with tissues that were stained negative for both HIF-1α and p-IkBα (P = .005). Moreover, a high degree of correlation was observed between protein expression of HIF-1α and phosphorylation level of IkBα (P = .002). These statistical analysis results showed significant correlations among EGFR mutants, p-IkBα, HIF-1α, and PD-L1 protein levels in NSCLC tissues. In contrast, some other retrospective studies have reported that PD-L1 positivity was more frequent in NSCLC tissues carrying WT EGFR and other studies have shown no association between PD-L1 expression and EGFR mutations.50-53 The discrepancies among these studies might be caused by the heterogeneous study population and variable definitions of PD-L1 expression. Additionally, our present findings indicated the necessity to explore the effects of genetic and environmental factors on NF-κB and HIF-1α in the studying of PD-L1 expression regulation by EGFR mutants. Notably, several recent clinical trials and retrospective studies have revealed no efficacy of the PD-1/PD-L1 inhibition strategy in EGFR mutated NSCLC compared with WT EGFR.54,55 This lack of response might be partially attributed to the complexity of regulatory effects of EGFR mutants on PD-L1 expression and the supression of tumor-infiltrating lymphocytes caused by EGFR pathway activation, which is likely responsible for the uninfamed tumor microenvironment and immunosuppression.56,57

Taken together, our data indicated important roles of p-AKT, p-ERK, NF-κB, and HIF-1α and potential interplay and cooperation between NF-κB and HIF-1α in PD-L1 expression regulation by EGFR mutants in NSCLC cells. Considering the widespread existence of hypoxia in solid tumors and its induction effect on HIF-1α expression, the influence of driver mutants combined with hypoxic conditions on PD-L1 expression regulation and tumor immune escape merits further investigation in expanded NSCLC cases.

ACKNOWLEDGMENTS
This work was supported by: the National Natural Science Foundation Key Program (Grant Nos. 81630071 and 81330062); National Key Research and Development Project Precision Medicine Special Research (Grant No. 2016YFC0902300); National High Technology Research and Development Program 863 (Grant No. SS2015AA020403); Beijing Municipal Natural Science Foundation (Grant Nos. 7152029 and 7172045); Collaborative Innovation Center for Cancer Medicine; Peking University-Tsinghua University Joint Center for Life Sciences Clinical Investigator; CAMS Innovation Fund for Medical Sciences (Grant No. CIFMS 2016-12M-3-008); and National Natural Science Foundation (Grant Nos. 81101778; 81472206). This study was approved by both the Ethics and the Academic committees of Beijing Cancer Hospital, and informed consent was obtained from each subject.

CONFLICT OF INTEREST
The authors declare no potential conflict of interest.

REFERENCES
1. Siegel R, De Santis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-241.
2. Kocher F, Hilbe W, Seeber A, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer. 2013;87:193-200.
3. Korpanty GJ, Graham DM, Vincent MD, et al. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol. 2014;4:204.
4. Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552-563.
5. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
7. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813-824.
8. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.
9. Shi L, Chen S, Yang L, et al. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74.
10. Sanmaned MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014;20:256-261.
11. Fan Y, Ma K, Wang C, et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther. 2016;9:6075-6082.
12. Takada K, Okamoto T, Shojo F, et al. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol. 2016;11:1879-1890.
13. Wu P, Wu D, Li L, et al. PD-L1 and survival in solid tumors: a meta-analysis. PloS One. 2015;10:e0131403.
14. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015;51:221-228.
15. Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-(gamma) and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110:296-304.
16. Chen J, Feng Y, Lu L, et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology. 2012;217:385-393.
17. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008;105:20852-20857.
18. Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25:590-604.
19. Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non-small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371-2376.

ORCID
Rong Guo https://orcid.org/0000-0002-4453-4632
Yong Li https://orcid.org/0000-0003-0124-8334
